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Abstract The study was undertaken to evaluate macrophage-
derived chemokine (CCL22) levels in the peritoneal fluid (PF)
and plasma of patients with ovarian cancer (n=93) in relation
to regulatory T cells (Tregs; n=75). The peritoneal fluid
CCL22 concentrations were significantly higher in epithelial
ovarian cancer (EOC) patients than in patients with benign
tumors-serous cystadenoma (n=32). There was no difference
in plasma levels of CCL22 in EOC patients compared with the
non-cancer and healthy volunteers (n=10). There were no
significant differences in the plasma and PF CCL22 levels
based on tumor grade. However, women with stage IV FIGO
(International Federation of Gynecologists and Obstetricians)
had significantly higher plasma CCL22 levels than patients
with stages I and III. Women with stage I FIGO had signifi-
cantly higher PF CCL22 levels than patients with stages II and
III. Women with endometrioid cystadenocarcinoma had
higher PF CCL22 levels than women with undifferentiated
carcinoma. The percentage of tumor-infiltrating Tregs
(11.06 %) was significantly higher compared to PF (3.05 %)
and peripheral blood (PB) (2.01 %). Moreover, the percentage
of Tregs was higher in the PF than in the PB of EOC patients.
There were no significant differences in the PB, PF, and
tumor-infiltrating Tregs percentage based on tumor stage,
grade, or histology. Elevated levels of CCL22 found in the
ascites could create a chemokine gradient aiding in Treg cells
migration. Increased Tregs percentage in the local microenvi-
ronment of ovarian cancer might be an important mechanism
of immunosuppression.
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Introduction
The development of epithelial ovarian cancer (EOC) is asso-
ciated with several immunosuppressive elements, involving
regulatory T cells (Tregs) activity in the tumor microenviron-
ment. It was shown that infiltration of ovarian cancers by
Tregs suppresses tumor-specific T cell immune response and
contributes to the tumor growth in vivo [1]. It has also been
documented that Tregs can inhibit the local immune response
through both direct cell-to-cell contact and secretion of immu-
nosuppressive cytokines: TGF-β and IL-10 [reviewed in 2].
Tregs are a heterogeneous CD4+ T cell subpopulation,
which are characterized by coexpression of CD25 and other
Treg characteristic markers, such as a glucocorticoid-induced
tumor necrosis factor receptor (GITR), a cytotoxic T lympho-
cyte antigen-4 (CTLA-4), and forkhead box protein 3
(FoxP3), which is a highly specific and reliable marker set
for primary human Tregs [3].
In 2001, Woo et al. [4] detected an increased percentage of
Tregs in women with late stage ovarian cancer. Similarly,
Curiel et al. [1] found large numbers of Tregs in malignant
ascites and in the tumor mass of patients with EOC and
showed a strong association of Tregs with poor survival. An
independent study by Wolf et al. [5] confirmed that a high
expression of the FoxP3 on Tregs is a negative prognostic
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factor for both progression-free and overall survival in EOC
patients. In contrary to the previous studies, Leffers et al. [6]
and Milne 2009 et al. [7] showed that tumor-infiltrating Tregs
were an independent positive factor for disease-specific sur-
vival in EOC patients. Therefore, the data concerning the im-
portance of Tregs in affecting ovarian cancer patients' out-
come is controversial.
A few studies have demonstrated the importance of the
macrophage-derived chemokine (CCL22) and its receptor
CCR4 in the migration of Tregs [8, 1, 9, 10]. The
macrophage-derived chemokine is produced constitutively
by macrophages [11, 1], monocyte-derived dendritic cells
[11, 1, 12, 13], activated natural killer (NK) cells [10], acti-
vated T cells [11, 14], and epithelial cells [15, 14]. Recently, it
has been reported that several solid tumor cells, including
ovarian [1], breast [10, 9, 16], prostate [17], gastric [18], and
esophageal tumor cells [19], release CCL22.
CCL22 plays an important role in a variety of diseases,
including allergic rhinitis [20], atopic dermatitis [21], and
lymphoma [22]. The role of CCL22 in malignant diseases
has not been investigated extensively. Li and co-workers
[16] have demonstrated that breast tumor cell-derived
CCL22 can serve as an independent prognostic predictor of
breast cancer patient’s survival. CCL22 might be also impor-
tant for the immunology of ovarian cancer. It influences mi-
gration of activated T cells [23], activated NK cells, mono-
cytes, andmonocyte-derived dendritic cells [11]. It was shown
that CCL22 is also a chemoattractant for regulatory Tcells [1].
In this study, we investigated the concentrations of CCL22
in the peritoneal fluid and plasma of patients with malignant
and benign ovarian disease and assessed relationship between
peritoneal fluid (PF) and peripheral blood (PB) regulatory T
cells and CCL22. To our knowledge, there are no previous
reports of the plasma and peritoneal fluid CCL22 and triple
stained (CD4+CD25highFoxP3+) Tregs percentage in women




A total of 93 women with histologically confirmed ovarian
cancer were enrolled in this study. Clinical stage was deter-
mined according to FIGO (International Federation of Gyne-
cologists and Obstetricians) classification [24]. Tumors were
graded and classified according to Shimizu-Silverberg grad-
ing system by two independent gynecological pathologists
[25]. The clinical and pathological characteristics of the
EOC patients are summarized in Table 1. None of the women
received chemotherapy before surgery. The reference group
consisted of 32 patients with benign tumors (histology: serous
cystadenoma), with no evidence of malignancies or pelvic
adhesions. The control group consisted of ten healthy periph-
eral blood donors. Informed consent was obtained from all
individual participants included in the study. The study was
approved by Lublin Medical University Ethics Committee.
Methods
Peripheral blood was collected in heparinized tubes. Peritone-
al fluid specimens were obtained at the time of surgery. Plas-
ma and PF samples were rendered cell-free by centrifugation
at 1500 rpm for 10 min and stored at −80 °C before being
tested by enzyme-linked immunosorbent assay (ELISA).
CCL22 concentrations in plasma and PF were determined
by Immunoassay kit (Research and Diagnostic Systems, Min-
neapolis, Minnesota, USA) following the manufacturer’s pro-
tocol. Concentrations of CCL22 were calculated by interpola-
tion from a standard curve. The sensitivity of the CCL22
ELISA was 62.5 pg/ml. All samples were assayed in
duplicate.
Cell preparation
PF and PB were taken into heparinized tubes (sodium hepa-
rin). In the non-cancer group, all visible PF was aspirated
during surgical procedure from the anterior and posterior
cul-de-sacs, under direct vision to avoid blood contamination.
All women had venous blood samples collected before the
surgical procedure. PF and PB mononuclear cells (n=75)
were isolated by density gradient centrifugation on
Table 1 Patient’s characteristics
Parameters Value
Patient age, n (min-max)
Ovarian cancer 55 (24–89)
Serous cystadenoma 27 (18–76)
Histology, n (%)
Serous cystadenocarcinoma (S) 34 (36.55)
Endometrioid cystadenocarcinoma (E) 24 (25.80)
Undifferentiated carcinoma (U) 23 (24.73)
Mucinous cystadenocarcinoma (M) 12 (12.90)
Serous cystadenoma 32 (100 %)
Grading, n (%)
G II 35 (37.63)
G III 58 (62.36)
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Lymphoprep (Nycomed, Norway) for 25 min at 600 g at room
temperature. Interface cells were collected and washed twice
in phosphate-buffered saline (PBS).
Tumor-infiltrating lymphocytes (TILs) were harvested
from 33 patients and isolated by discontinuous Ficoll
gradient as described by Knutson et al. [26]. Briefly,
the lymphocytes were separated from the tumor cells
by centrifugation of the cell suspension on a two layer
Ficoll gradient, 100 % layer on the bottom and 75 %
layer on top. The isolated cells were frozen in storage
medium (composition: 10 % dimetyl sulfoxide (Sigma-
Aldrich, USA), 20 % human albumin (Baxter, Poland),
and 70 % RPMI 1640 medium (PAA, Austria)) and kept
in liquid nitrogen to the time of flow cytometry analy-
sis of Tregs. The percentage of Tregs was determined
using the Human Treg Flow Kit from BioLegend (San
Diego, CA, USA) according to the manufacturer’s
instructions.
T regulatory cells were evaluated via analysis of the surface
expression of CD4 and CD25 antigens, as well as intracellular
expression of FoxP3. The isolated cells were incubated with
mAbs for surface staining such as anti-CD4 PE-Cy5 and anti-
CD25 PE (BioLegend). We also evaluated expression of
CCR4 receptor on Tregs using anti-CCR4 PE-Cy7 monoclo-
nal antibody and relevant izotype control (BD Pharmingen).
Next, cells were permeabilized and stained with anti-FoxP3
Alexa Fluor 488 and relevant isotype controls (BioLegend).
After the intracellular staining, cells were washed and estimat-
ed by flow cytometry.
Flow cytometric analysis
Flow cytometric analysis of stained samples was performed
with a FacsCanto flow cytometer (Becton Dickinson, San
Jose, California, USA). A total of 100,000 events were ac-
quired and analyzed using FacsDiva software. Cell debris
and dead cells were excluded from the analysis based on scat-
ter signals. T regulatory cells were characterized as
CD4+CD25high expressing FoxP3+. Results are expressed as
a percentage of Tregs among CD4+ T cells.
Statistical analysis
Data were presented as medians with the interquartile
ranges. The Wilcoxon paired test was used to compare
the results in PF, PB, and tissue. The Mann-Whitney U
test was applied to the results of statistical comparison
between the studied groups. Spearman’s rank test was
used to assess the relationship between concentrations of
CCL22 and Tregs numbers. p value less than 0.05 was con-
sidered statistically significant.
Results
Concentration of CCL22 in the peritoneal fluid and plasma
of women with ovarian cancer and serous cystadenoma
and in the control group
The concentrations of CCL22 in the peritoneal fluid and plas-
ma of patients with ovarian tumors and normal control group
are presented in Table 2.
CCL22 levels detected in the peritoneal fluid of women
suffering from ovarian cancer were found to be significantly
higher (p<0.001) than those with benign ovarian disease.
CCL22 levels detected in the peritoneal fluid of women
suffering from ovarian cancer were found to be significantly
higher (p=0.00002) than in the plasma. In contrary, in the
group of patients with benign ovarian disease, the CCL22
levels were significantly higher in the plasma (p<0.001) than
in the peritoneal fluid (Table 2).
There was no significant difference in the plasma CCL22
levels among the ovarian cancer patients, the benign ovarian
tumor patients, and the control group (Table 2).
Concentration of CCL22 in patients with different stage,
grade, and histologic type of ovarian cancer
The PF CCL22 levels in patients with FIGO stage I of ovarian
cancer were significantly higher than in women with FIGO
stages II and III (p<0.05; Fig. 1). Women with endometrioid
cystadenocarcinoma had significantly higher (p<0.05) PF
CCL22 levels than patients with undifferentiated carcinoma
(Fig. 2).
The plasmaCCL22 levels in patients with FIGO stage IVof
ovarian cancer was significantly higher than in women with
FIGO stage I (p=0.003) and FIGO stage III (p=0.02) (Fig. 1).
There were no significant differences in the plasma CCL22
levels in relation to histology (Fig. 2).
Table 2 Levels of CCL22 (pg/ml) in the plasma and peritoneal fluid
(PF) of patients with ovarian tumors and normal donors







299.81 237.63-459.53 435.39b 328.65-607.91
Serous cystadenoma
(n=32)




a p<0.001 in relation to PF of patients with serous cystadenoma
b p<0.001 in relation to PF of patients with serous cystadenoma and in
relation to plasma of EOC patients
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There were no significant differences in the plasma and PF
CCL22 levels in relation to tumor grade (Table 3).
The percentage of Tregs in women with ovarian cancer
and benign tumors
The percentage of tumor-infiltrating Tregs was significantly
higher (11.06 %; interquartile ranges 6.87 to 19.28 %) com-
pared to PF (3.05 %; interquartile ranges 1.08 to 4.99 %) and
PB (2.01 %; interquartile ranges 1.09 to 3.45 %). Moreover,
the percentage of Tregs was higher (p=0.0004) in the PF than
in the PB of EOC patients.
There were no significant differences in the PB, PF, and
tumor-infiltrating Tregs levels based on tumor stage (Fig. 3),
grade, or histology (p>0.05).
The percentage of Tregs in the PB of women with ovarian
cancer (2.01 %; interquartile ranges 1.09 to 3.45 %) was
higher than in patients with serous cystadenoma (0.94 %; in-
terquartile ranges 0.52 to 2.68 %), but the difference was not
statistically significant (p=0.42).
Relationship between concentration of CCL22 and Tregs
in the PF and PB of EOC patients
The percentage of CD4+CD25highFoxP3+ cells positively cor-
related with the concentration of peritoneal fluid CCL22
levels (RSpearman=0.44; p=0.0001) (Fig. 4).There was no
statistically significant correlations between the plasma
CCL22 levels and Tregs in PB (R=−0.12; p=0.81).
The percentage of Tregs expressing CCR4
The percentage of CD4+CD25highFoxP3+ cells expressing
CCR4 receptor in the PB was slightly higher than in the PF,
but no significant differences (p=0.06) were observed
(Fig. 5).
Discussion
The results of the present study show for the first time positive
relationship between triple stained CD4+CD25highFoxP3+
cells and concentration of CCL22 chemokine in the peritoneal
fluid of patients with ovarian cancer. It is, therefore, tempting
to speculate that Tregs accumulation in the peritoneal cavity of
EOC patients is related to their chemotaxis from peripheral
blood. It was also interesting whether changes in the
Fig. 1 Levels of CCL22 (pg/ml) in the plasma and peritoneal fluid (PF)
of patients with different FIGO stage of ovarian cancer [line at median;
floating bars (min to max)]
Fig. 2 Levels of CCL22 (pg/ml) in the plasma and peritoneal fluid (PF)
of patients with different histological type of ovarian cancer [line at me-
dian; floating bars (min to max)]
Table 3 Levels of CCL22 (pg/ml) in the plasma and peritoneal fluid
(PF) of patients with ovarian cancer in relation to tumor grade





G2 (n=35) 278.67 205.12–420.01 443.82a 345.22–697.84
G3 (n=58) 321.27 262.77–504.19 435.39b 314.60–597.12
a p=0.002 in relation to plasma of G2 patients
b p=0.003 in relation to plasma of G3 patients
Fig. 3 The percentage of PB, PF, and tumor-infiltrating Tregs in women
with different FIGO stage of ovarian cancer [line at median; floating bars
(min to max)]
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concentration of CCL22 and the percentage of Tregs may
depend on the stage, grade, and histological type of the tumor.
To our knowledge, CCL22 levels and frequency of triple
stained CD4+CD25highFoxP3+ cells have not been studied so
far in EOC patients with different stage, grade, and histolog-
ical type of the tumor.
We found concentrations of CCL22 in the peritoneal fluid
to be significantly elevated in women with EOC, as compared
to benign ovarian tumor patients. Additionally, the CCL22
levels in the peritoneal fluid of EOC patients were significant-
ly higher than the plasma levels. Our results suggest that
macrophage-derived chemokine, CCL22, may be produced
locally by ovarian tumor cells. This hypothesis is consistent
with the results of Curiel et al. [1] who clearly demonstrated
expression of CCL22 mRNA in tumor tissue and ascites cells
of EOC patients, and no such evidence in PBMC or normal
ovaries. The authors also detected large amounts of CCL22 in
tumor ascites, but only in 18 patients with EOC. However, no
CCL22 concentration in the PF of women with benign ovarian
tumors was assessed. Interestingly, our data suggest that ma-
lignant and benign tumors induce significantly different levels
of CCL22 secretion.
Fig. 4 Correlations between
CCL22 and Tregs in patients with
ovarian cancer
Fig. 5 The percentage of Tregs
expressing CCR4 in the PB and
PF of women with ovarian cancer
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The other studies showed that myeloid dendritic cells may
be the source of CCL22 [11, 1, 12, 13]. Our previous studies
have demonstrated that the percentage of myeloid DC in
mononuclear cells was significantly higher in the PF than in
PB of ovarian cancer patients [27]. However, Goyne et al. [28]
recently proved that primary tumor ascites CD14+ cells, rather
than tumor cells, were the predominant source of CCL22 in a
cohort of nine patients with EOC.
The results of our group showed that the tissue and PF
environment in women with malignant ovarian tumors con-
tains considerably more Tregs than PB. This is in agreement
with the results of previously published studies by Li et al.
[29], who showed slightly increased Tregs percentage in the
tumor tissue compared with PB and PF but the results did not
achieve conventional level of statistical significance. Similarly
to our results, Curiel et al. [1] reported significantly higher
percentage of Tregs in the ascites than PB of ovarian cancer
patients. The authors identified Tregs using flow cytometry by
the expression of CD4+CD25+ antigens. In our study, we
phenotyped Tregs as triple stained CD4+CD25highFoxP3+
cells. It should be emphasized that intracellular FoxP3 expres-
sion is nowadays the best marker available for Tregs [3]. Our
observation appears to support the hypothesis that peripheral
blood Tregs are specifically recruited into PF and cancer tis-
sue. The reason for the accumulation of Tregs in the PF and
cancer tissue has not been clearly explained yet.
Studies by Curiel et al. [1] suggest that CCL22 chemokine
mediates Tregs trafficking in vitro and may recruit Tregs to the
tumor. Moreover, the authors have shown that tumor Tregs
express functional CCR4, the receptor for CCL22, and can
migrate to CCL22, present in the tumor microenvironment.
Interestingly, according to our data, the highest concentrations
of CCL22 and the highest percentage of Tregs were found in
the PF of women with EOC. Consistently with previous re-
sults [8, 1], our data showed that percentage of triple stained
CD4+CD25highFoxP3+ cells expressed CCR4 receptor. More-
over, the percentage of CD4+CD25highFoxP3+ cells positively
correlated with the concentration of PF CCL22 levels. This
raises the possibility that high ascites CCL22 levels detected
in our study may be a potent chemoattractant for Tregs ex-
pressing CCR4. It is worth noting that, in patients with serous
cystadenoma, in contrary to patients with EOC, levels of
CCL22 were consistently higher in the plasma than in PF. It
has been also reported that Tregs can be converted from non-
Tregs by high levels of TGF-β [30, 31, 16]. The previous
study in hepatocellular carcinoma provided direct evidence
that TGF-β could suppress the expression of miR-34a,
resulting in the enhanced production of CCL22 and recruit-
ment of Tregs. The authors speculate that Tregs accumulation
may be induced through the interaction of TGF-β and CCL22
[32].
In the following study, we have carefully analyzed the con-
centration of CCL22 in the PF and plasma of women with
different stages, grades, and histological types of tumor. We
demonstrated that the plasma CCL22 concentrations are the
highest in patients with FIGO stage IVof ovarian cancer. The
peritoneal fluid CCL22 levels were the highest in patients with
FIGO stage I of EOC. There were also significant differences
in the PF CCL22 levels based on tumor histology. Unexpect-
edly, the highest concentrations of CCL22 were found in the
PF of women with endometrioid cystadenocarcinoma and in
plasma of women with mucinous cystadenocarcinoma. These
data led us to conclude that CCL22 production in ovarian
cancer patients depends on the stage and histological type of
the tumor cells.
The results of our study suggest that increased level of
CCL22 in the PF of women suffering from EOC may have
an important role in migration of Tregs to the peritoneal cavity
and thus may be responsible for suppression of local immune
responses.
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